Skip to content

Role of microRNA in the Development of Cutaneous Squamous Cell Carcinoma

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01143311
Enrollment
20
Registered
2010-06-14
Start date
2010-06-30
Completion date
2011-04-30
Last updated
2011-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer of the Skin

Brief summary

The aim of this study is to analyze the differential expression of the miR transcriptome in the distinctive stages of the development of cutaneous squamous cell carcinoma (C-SCC). In this aim the investigators plan to recruit a cohort of 20 patients suffering of C-SCC and to collect from each of them, biopsies corresponding to i) non UV-exposed areas ii) UV-exposed areas, iii) actinic keratosis and iv) tumoral regions. Total RNAs will be prepared from each biopsy and the miRNA profiles will be characterized using a dedicated miR array.

Interventions

GENETICArm A

4 distinct biopsies will be taken 1. in a non UV-exposed area (inner arm) 2. in a UV-exposed area (external surface of the forearm) 3. in a pretumoral region (actinic keratosis) 4. inside the tumor

Sponsors

Centre Hospitalier Universitaire de Nice
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patient older than 40th, suffering of a C-SCC * letter of consent signed by the patient * to be registered to social security

Exclusion criteria

* Pregnant women or breastfeeding. * Small C-SCC (size \< 6mm) * Allergy to Xylocaine * All vulnerable (minor, adult guardianship…)

Design outcomes

Primary

MeasureTime frameDescription
miRNAs1 yearWe will select the miRNAs differently expressed between biopsies obtained respectively from areas of normal, pretumoral and tumoral areas (candidate miRs = miRs potentially involved in tumor transformation of epidermal keratinocytes). This will be assessed by analyzing in each of the biopsies from each patient, the expression of different miRs that are known to date, using a dedicated microarray, then by checking the data obtained by quantitative PCR.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026